Aldosterone and the kidney: A rapidly moving frontier (an update)

Nephrology Dialysis Transplantation

Volumn 29, Issue 11, 2014, Pages 2012-2019

  Ritz, Eberhard ^a   Tomaschitz, Andreas ^b,c  

^a Nierenzentrum   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Specialist Clinic for Rehabilitation PV Bad Aussee   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DIURETIC AGENT; EPLERENONE; KLOTHO PROTEIN; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; OSILODROSTAT; PATIROMER; PLACEBO; SM 368229; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; DIABETES MELLITUS; DIET THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE ACTION; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; CHRONIC KIDNEY FAILURE; CYTOLOGY; KIDNEY; METABOLISM; NEPHRON; PATHOLOGY; PHYSIOLOGY;

ALDOSTERONE; ANIMALS; HUMANS; KIDNEY; NEPHRONS; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84929092638     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft035     Document Type: Review

References (59)

1. Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens 2012; 21: 147-156
2. Fourkiotis VG, Hanslik G, Hanusch F et al. Aldosterone and the kidney. Horm Metab Res 2012; 44: 194-201
3. Fels J, Oberleithner H, Kusche-Vihrog K. Menage a trois: aldosterone, sodium and nitric oxide in vascular endothelium. Biochim Biophys Acta 2010; 1802: 1193-1202
4. Büssemaker E, Hillebrand U, Hausberg M et al. Pathogenesis of hypertension: interactions among sodium, potassium, and aldosterone. Am J Kidney Dis 2010; 55: 1111-1120
5. Shimosawa T,Mu S, Shibata S et al. The kidney and hypertension: pathogenesis of salt-sensitive hypertension. Curr Hypertens Rep 2012; 14: 468-472
6. Terata S, Kikuya M, Satoh M et al. Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study. J Hypertens 2012; 30: 1632-1638
7. Fox CS, Gona P, Larson MG et al. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 2010; 21: 2143-2149
8. Ando K, Ohtsu H, Arakawa Y et al. Rationale and design of the eplerenone combination versus conventional agents to lower blood pressure on urinary antialbuminuric treatment effect (EVALUATE) trial: a doubleblinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res 2010; 33: 616-621
9. Boesby L, Elung-Jensen T, Klausen TW et al. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A Randomized Cross-Over Study. PLoS One 2011; 6: e26904
10. Quinkler M, Zehnder D, Eardley KS et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005; 112: 1435-1443
11. Fourkiotis VG, Vonend O, Diederich S et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2012; 168: 75-81
12. Leung JC, Chan LY, Tang SC et al. Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone. J Transl Med 2011; 9: 169
13. Bomback AS, Klemmer PJ. Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012; 33: 119-124
14. Rossignol P, Cleland JG, Bhandari S et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 2012; 125: 271-279
15. Nielsen SE, Persson F, Frandsen E et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 2012; 29: e184-e190
16. Buysse JM, Huang IZ, Pitt B. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 2012; 8: 17-28
17. Pitt B, Anker SD, Bushinsky DA et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebocontrolled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32: 820-828
18. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012; 81: 955-968
19. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 2011; 79: 1051-1060
20. Edwards NC, Steeds RP, Stewart PM et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009; 54: 505-512
21. Drechsler C, Ritz E, Tomaschitz A et al. Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. Eur Heart J 2013; 34: 578-587
22. Lepenies J, Quinkler M. MR Blockade in patients with chronic renal disease-not the more the merrier, but the earlier the better. Nephrol Dial Transplant 2006; 21: 3343-3344
23. Funder JW. Aldosterone and mineralocorticoid receptors: a personal reflection. Mol Cell Endocrinol 2012; 350: 146-150
24. Queisser N, Amann K, Hey V et al. Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo. Free Radic Biol Med 2013; 54: 1725
25. Terada Y, Ueda S, Hamada K et al. Aldosterone stimulates nuclear factorkappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum-and glucocorticoid-inducible protein kinase-1. Clin Exp Nephrol 16: 81-88
26. Kasal DA, Barhoumi T, Li MWet al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 59: 324-330
27. Kawarazaki H, Ando K, Shibata S et al. Mineralocorticoid receptor-Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats. J Hypertens 30: 1977-1985
28. Fu Y, Hall JE, Lu D et al. Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. Hypertension 59: 599-606
29. Qin D, Morita H, Inui K et al. Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis. J Nephrol p. 0
30. Barrera-Chimal J, Pérez-Villalva R, Rodríguez-Romo R et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 2013; 83: 93-103
31. Fischer SS, Kempe DS, Leibrock CB et al. Hyperaldosteronism in Klothodeficient mice. Am J Physiol Renal Physiol 299: F1171-F1177
32. Naito Y, Fujii A, Sawada H et al. Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J Hypertens 30: 2192-2201
33. Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal disease. Am J Kidney Dis 1992; 20: 580-584
34. Nankivell BJ, Chen J, Boadle RA et al. The role of tubular iron accumulation in the remnant kidney. J Am Soc Nephrol 1994; 4: 1598-1607
35. Nariai T, Fujita K, Mori Met al. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats Pharmacology 89: 44-52
36. Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens 31: 3-15
37. Andersen K, Hartman D, Peppard TH et al. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich) 14: 580-587
38. Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant 2013; 28: 36-43
39. Calhoun DA, White WB, Krum H et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo-and active-controlled phase 2 trial. Circulation 124: 1945-1955
40. Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci 32: 734-739
41. Peti-Peterdi J. High glucose and renin release: the role of succinate and GPR91. Kidney Int 78: 1214-1217
42. Peti-Peterdi J, Gevorgyan H, Lam L et al. Metabolic control of renin secretion. Pflugers Arch 2013; 465: 53-58
43. Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005; 46: 584-590
44. Lee SH, Yoo TH, Nam BY et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009; 297: F1381-F1390
45. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 31: 541-550
46. Matavelli LC, Siragy HM. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. J Cardiovasc Pharmacol 2013; 61: 17-22
47. Toyonaga J, Tsuruya K, Ikeda H et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 26: 2475-2484
48. Deliyanti D, Miller AG, Tan G et al. Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy. Hypertension 59: 607-613
49. Briones AM, Nguyen Dinh Cat A, Callera GE et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59: 1069-1078
50. Tokuyama H, Wakino S, Hara Y et al. Role of mineralocorticoid receptor/ Rho/Rho-kinase pathway in obesity-related renal injury. Int J Obes (Lond) 36: 1062-1071
51. O'Seaghdha CM, Hwang SJ, Vasan RS et al. Correlation of renin angiotensin and aldosterone system activity with subcutaneous and visceral adiposity: the framingham heart study. BMC Endocr Disord 2012; 12: 3
52. Muller-Fielitz H, Lau M, Jöhren O et al. Blood pressure response to angiotensin II is enhanced in obese Zucker rats and is attributed to an aldosterone-dependent mechanism. Br J Pharmacol 166: 2417-2429
53. Boscaro M, Giacchetti G, Ronconi V. Visceral adipose tissue: emerging role of gluco-and mineralocorticoid hormones in the setting of cardiometabolic alterations. Ann N Y Acad Sci 1264: 87-102
54. Nagase M, Matsui H, Shibata S et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007; 50: 877-883
55. Flynn C, Bakris GL. Interaction between adiponectin and aldosterone. Cardiorenal Med 1: 96-101
56. Doi M, Takahashi Y, Komatsu R et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 16: 67-74
57. Doi M. Circadian clock-deficient mice as a tool for exploring disease etiology. Biol Pharm Bull 35: 1385-1391
58. Susa K, Sohara E, Isobe K et al. WNK-OSR1/SPAK-NCC signal cascade has circadian rhythm dependent on aldosterone. Biochem Biophys Res Commun 427: 743-747
59. Gomez-Sanchez EP, Gomez-Sanchez CE. Central regulation of blood pressure by the mineralocorticoid receptor. Mol Cell Endocrinol 350: 289-298